A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MOGAD / myelin oligodendrocyte glycoprotein antibody-associated disease

[Related PubMed/MEDLINE]
Total Number of Papers: 54
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MOGAD  (>> Co-occurring Abbreviation)
Long Form:   myelin oligodendrocyte glycoprotein antibody-associated disease
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 "Peppering the pons": CLIPPERS or myelin oligodendrocyte glycoprotein associated disease? CLIPPERS
2021 Acute retrobulbar optic neuritis with anti-myelin oligodendrocyte glycoprotein antibody-associated disease complicated with microscopic polyangiitis: A case report. MPA, MPO-ANCA, NMOSD, ON
2021 Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? GCIPL, ON, pRNFL, SD-OCT, VEP
2021 Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina. GEEs, NMOSD, PR
2021 Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. GM, HC, MS, WM
2021 Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica. AQP4, CVS, FLAIR, MRI, MS, NMOSD
2021 Clinical and neuroimaging findings in MOGAD-MRI and OCT. ---
2021 Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder. AQP4, CI, NMOSD, OR
2021 Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. AQP4-IgG-NMOSD, MS
10  2021 Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis. CNS, FA, HC, MRI, MS, NMOSD-AQP4
11  2021 Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study. 3D-FLAIRGd, 3D-T1w, CCLs, IC-SP, IQR, LC, LMCE, MRI, MS, RRMS
12  2021 COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2. ADEM, AHNE/AHLE, COVID-19
13  2021 COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry. COVID-19, MS, NMOSD
14  2021 Isolated Double-Positive Optic Neuritis: A Case of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody Seropositivity. MOG, NMO, ON
15  2021 Modified models to distinguish central nervous system demyelinating diseases with brain lesions. PCA, RRMS
16  2021 Myelin oligodendrocyte glycoprotein antibody-associated disorders coexisting with ankylosing spondylitis: Potential association between demyelination and tumor necrosis factor inhibitors. AS, TNF-alpha
17  2021 Myelin-oligodendrocyte glycoprotein antibody-associated disease. NMOSD
18  2021 NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders. NfL
19  2021 Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. ---
20  2021 Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. CNS, NMOSDs
21  2021 Pain, depression, and quality of life in adults with MOG-antibody-associated disease. ADL, HRQoL
22  2021 Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. MS, NMOSD
23  2021 Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. PPV
24  2021 Potential of PINK1 and PARKIN Proteins as Biomarkers for Active Multiple Sclerosis: A Japanese Cohort Study. CSF, MS, NMOSD, PINK1
25  2021 Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders. PIRA
26  2021 Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. AQP4-Ab, HCs, NMOSD, RRMS, sGFAP, sNfL
27  2021 The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis. CNS, EDSS, MS, NMOSD-AQP4-Ab, SPMS
28  2021 Two cases of myelin oligodendrocyte glycoprotein antibody-associated disease presenting with Cauda Equina Syndrome without conus myelitis. ---
29  2021 [Treatment of antibody-mediated encephalomyelitis : Strategies for the treatment of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease]. GFAP, MS, NMOSD
30  2020 Alterations in the Retinal Vascular Network and Structure in MOG Antibody-Associated Disease: An Optical Coherence Tomography Angiography Study. MOG-Ab, ON
31  2020 Anti-MOG-associated demyelinating disorders: two sides of the same coin. ---
32  2020 Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment. ---
33  2020 Brain structural and functional alterations in MOG antibody disease. DC, FA, GM, HC, MD
34  2020 Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. AQP4-IgG-NMOSD, CSF, MS
35  2020 Clinical commentary on the broadening spectrum of myelin oligodendrocyte glycoprotein-associated disorder (MOGAD). ---
36  2020 Dysphagia in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody disease as a surrogate of brain involvement? EDSS, FEES, NMOSD
37  2020 E.U. paediatric MOG consortium consensus: Part 2 - Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. ADS, MS, NMOSD
38  2020 E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. IVIG, IVMP, RTX
39  2020 MOGAD: How It Differs From and Resembles Other Neuroinflammatory Disorders. MS, NMOSD
40  2020 MRI characteristics of MOG-Ab associated disease in adults: An update. AQP4-NMOSD, MRI, MS
41  2020 Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis with considerable white blood cell elevation in cerebrospinal fluid. ---
42  2020 Myelin-oligodendrocyte-glycoprotein antibody associated disorders (MOGAD): More than meets the eye. ---
43  2020 Neutrophil-to-lymphocyte ratio correlates with disease activity in myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) in children. NLR
44  2020 Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series. NMOSD
45  2020 Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review. ON
46  2020 Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. COVID-19, EDSS, NMOSD
47  2020 Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease. ORs
48  2020 Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. AQP4-Abs, EDSS, GFAP, NfL, NMOSD
49  2020 Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD). IDDs, IFN, IL, MS, Th, TNF
50  2020 Treatment of MOG antibody associated disorders: results of an international survey. IVIg, MT, PE
51  2020 Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. RTX
52  2020 Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. CSF
53  2020 [Analysis of magnetic resonance imaging characteristics in Chinese patients with myelin oligodendrocyte glycoprotein antibody associated disorders]. MRI
54  2019 Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)? ---